Protagonist Therapeutics Inc (PTGX)

04:03 AM

PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade

04:03 AM

01:52 AM

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India

01:52 AM

01:28 AM

Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - AD HOC NEWS

01:28 AM

12:55 PM

Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet

12:55 PM

11:15 AM

PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView

11:15 AM

08:53 AM

PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus

08:53 AM

07:28 AM

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com

07:28 AM

07:00 AM

Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView

07:00 AM

Jul 06, 2026

Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD - Investing.com

Jul 06, 2026

Jul 04, 2026

PTGXProtagonist Therapeutics Inc Volatility & Greeks - Finviz

Jul 04, 2026

Jul 03, 2026

Protagonist Therapeutics updates its pipeline. PTGX focuses on peptide drug development - AD HOC NEWS

Jul 03, 2026

Jul 02, 2026

Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock - Yahoo Finance

Jul 02, 2026

Jul 01, 2026

Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire

Jul 01, 2026

Jul 01, 2026

Protagonist Therapeutics awards new hires stock options and RSUs - Stock Titan

Jul 01, 2026

Jul 01, 2026

Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa

Jul 01, 2026

Jun 28, 2026

Why (PTGX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jun 28, 2026

Jun 26, 2026

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits

Jun 26, 2026

Jun 26, 2026

Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 26, 2026

Jun 25, 2026

Form 4 Protagonist Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTGX) - TradingView

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics director Waddill sells $1.06m in stock By Investing.com - Investing.com Australia

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics director Waddill sells $1.06m in stock - Investing.com

Jun 25, 2026

Jun 25, 2026

Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan - Stock Titan

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics stock hits all-time high at 124.97 USD By Investing.com - Investing.com South Africa

Jun 25, 2026

Jun 25, 2026

PTGX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics stock hits all-time high at 124.97 USD - Investing.com

Jun 25, 2026

Jun 25, 2026

Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView

Jun 25, 2026

Jun 24, 2026

Why Is Silence Therapeutics Stock Soaring Wednesday?Silence Therapeutics (NASDAQ:SLN) - Benzinga

Jun 24, 2026

Jun 24, 2026

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest - Sahm

Jun 24, 2026

Jun 24, 2026

Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com - Investing.com India

Jun 24, 2026

Jun 23, 2026

PTGX (NASDAQ) Form 144: Director-linked 9,000-share sales and option exercise - Stock Titan

Jun 23, 2026

Jun 22, 2026

Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo

Jun 22, 2026

Jun 20, 2026

Protagonist Therapeutics (PTGX) Edges Higher, Testing Key Resistance Zone Near $118.5Covered Call Trade - Město Břeclav

Jun 20, 2026

Jun 19, 2026

Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com - Investing.com India

Jun 19, 2026

Jun 18, 2026

Protagonist Therapeutics Adopts 2026 Equity Incentive Plan Following Shareholder Approval - Minichart

Jun 18, 2026

Jun 18, 2026

Protagonist Therapeutics (PTGX) OKs 2026 equity plan and re-elects directors at annual meeting - Stock Titan

Jun 18, 2026

Jun 18, 2026

Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat

Jun 18, 2026

Jun 18, 2026

Protagonist Therapeutics stock hits all-time high at 113.75 USD - Investing.com

Jun 18, 2026

Jun 18, 2026

Protagonist Therapeutics Inc (PTGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 18, 2026

Jun 18, 2026

Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026

Jun 18, 2026

Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 18, 2026

Jun 17, 2026

Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026

Jun 17, 2026

Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Protagonist Therapeutics Inc (PTGX) Institutional Confidence - TradingKey

Jun 17, 2026

Jun 17, 2026

Protagonist Therapeutics Inc - TradingKey

Jun 17, 2026

Jun 17, 2026

Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026